Spots Global Cancer Trial Database for adult acute myeloid leukemia with t(15;17)(q22;q12)

Every month we try and update this database with for adult acute myeloid leukemia with t(15;17)(q22;q12) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies	NCT01175785	Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Myelo...	umbilical cord ... fludarabine pho... cyclophosphamid... ex vivo-expande... total-body irra... cyclosporine mycophenolate m... laboratory biom...	6 Months - 45 Years	Nohla Therapeutics, Inc.
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation	NCT00052520	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... B-cell Adult Ac... B-cell Childhoo... Childhood Chron... Childhood Myelo... Chronic Myelomo... Essential Throm... Polycythemia Ve... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... T-cell Adult Ac... T-cell Childhoo...	therapeutic all... aldesleukin peripheral bloo... allogeneic bone... laboratory biom... gene expression... immunologic tec... flow cytometry polymerase chai... cytogenetic ana... staining method	-	Fred Hutchinson Cancer Center
Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT00062075	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Recurrent Adult...	romidepsin	18 Years -	National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia	NCT00003868	Leukemia	cyclophosphamid... methotrexate allogeneic bone... peripheral bloo... iodine I 131 mo... radiation thera...	2 Years - 55 Years	Fred Hutchinson Cancer Center
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT02299518	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute...	mitoxantrone hy... etoposide cytarabine selinexor laboratory biom... pharmacological...	18 Years -	Ohio State University Comprehensive Cancer Center
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	NCT00445744	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child...	cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema...	- 65 Years	Fred Hutchinson Cancer Center
Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2	NCT00896701	Leukemia	flow cytometry immunologic tec... laboratory biom...	15 Years -	Alliance for Clinical Trials in Oncology
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD	NCT00914940	Graft Versus Ho... Leukemia Myelodysplastic...	Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted...	14 Years - 55 Years	Fred Hutchinson Cancer Center
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma	NCT00398138	Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton...	WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te...	18 Years - 120 Years	Memorial Sloan Kettering Cancer Center
Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission	NCT00005940	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye...	iodine I 131 mo... busulfan cyclophosphamid... allogeneic bone... allogeneic hema... peripheral bloo... cyclosporine methotrexate laboratory biom...	16 Years - 55 Years	Fred Hutchinson Cancer Center
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	NCT00475150	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult...	cediranib malea... laboratory biom...	18 Years -	National Cancer Institute (NCI)
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies	NCT00070538	Leukemia Myelodysplastic...	cytarabine laromustine	18 Years -	National Cancer Institute (NCI)
S9031-9333-0106-0112-A Study of Biomarkers in Samples From Patients With Acute Myeloid Leukemia Treated With Standard Chemotherapy With or Without Gemtuzumab Ozogamicin	NCT01503541	Leukemia	DNA analysis RNA analysis gene expression... mutation analys... polymerase chai... laboratory biom...	18 Years - 88 Years	SWOG Cancer Research Network
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia	NCT00528450	Leukemia	arsenic trioxid... idarubicin tretinoin	18 Years - 120 Years	Memorial Sloan Kettering Cancer Center
Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	NCT00079378	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Recurrent Small... Refractory Chro... Untreated Adult...	decitabine valproic acid pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	NCT00274807	Leukemia	filgrastim cytarabine etoposide mitoxantrone hy...	16 Years -	The Cleveland Clinic
Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS	NCT01141725	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Myelodysplastic... Untreated Adult...	bendamustine hy... idarubicin	50 Years -	Fred Hutchinson Cancer Center
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma	NCT00398138	Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton...	WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te...	18 Years - 120 Years	Memorial Sloan Kettering Cancer Center
Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First Remission	NCT00005940	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye...	iodine I 131 mo... busulfan cyclophosphamid... allogeneic bone... allogeneic hema... peripheral bloo... cyclosporine methotrexate laboratory biom...	16 Years - 55 Years	Fred Hutchinson Cancer Center
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT01707004	Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute...	decitabine fludarabine pho... busulfan cyclophosphamid... tacrolimus mycophenolate m... filgrastim total-body irra... allogeneic bone... laboratory biom...	18 Years - 75 Years	University of Wisconsin, Madison
Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML	NCT00871689	Leukemia	aldesleukin cyclophosphamid... fludarabine pho... umbilical cord ... total-body irra...	- 45 Years	Masonic Cancer Center, University of Minnesota
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia	NCT00016159	Leukemia	filgrastim lintuzumab arsenic trioxid... idarubicin tretinoin	-	Memorial Sloan Kettering Cancer Center
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD	NCT00914940	Graft Versus Ho... Leukemia Myelodysplastic...	Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted...	14 Years - 55 Years	Fred Hutchinson Cancer Center
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	NCT00445744	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child...	cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema...	- 65 Years	Fred Hutchinson Cancer Center
Empirical Versus Preemptive Antifungal Therapy	NCT01288378	Fungal Infectio... Leukemia Myelodysplastic...	caspofungin ace...	18 Years -	European Organisation for Research and Treatment of Cancer - EORTC
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	NCT00087204	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo...	becatecarin laboratory biom...	18 Years -	National Cancer Institute (NCI)
VNP40101M and Cytarabine in Treating Patients With Hematologic Malignancies	NCT00070538	Leukemia Myelodysplastic...	cytarabine laromustine	18 Years -	National Cancer Institute (NCI)
Relationship Between Natural Killer Cells' Ability to Kill Leukemia Cells and the Outcome of Patients With Acute Myeloid Leukemia Previously Treated With Interleukin-2	NCT00896701	Leukemia	flow cytometry immunologic tec... laboratory biom...	15 Years -	Alliance for Clinical Trials in Oncology
DNA Analysis of Tumor Tissue From Patients With Acute Myeloid Leukemia	NCT00897936	Leukemia	DNA methylation... comparative gen... fluorescence in... microarray anal... polymerase chai... diagnostic labo... immunologic tec...	18 Years - 120 Years	Eastern Cooperative Oncology Group
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome	NCT00119366	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Myelo... Chronic Myelomo... Previously Trea... Recurrent Adult... Recurrent Child... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Secondary Acute... Secondary Myelo...	iodine I 131 mo... fludarabine pho... total-body irra... allogeneic hema... peripheral bloo... cyclosporine mycophenolate m... laboratory biom...	16 Years - 50 Years	Fred Hutchinson Cancer Center
Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission	NCT01842139	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye...	basiliximab WT1 126-134 pep... Montanide ISA 5... poly ICLC laboratory biom...	18 Years - 85 Years	University of Chicago
CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT01768897	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult...	CPI-613 cytarabine mitoxantrone hy... laboratory biom... pharmacological...	18 Years -	Wake Forest University Health Sciences
Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia	NCT00100971	Leukemia	autologous tumo... therapeutic aut... tumor cell-deri...	18 Years -	Boston Medical Center
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer	NCT00296023	Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo...	18 Years - 75 Years	University of California, San Francisco
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia	NCT00093743	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... Fanconi Anemia Previously Trea...	fludarabine pho... cyclosporine total-body irra... allogeneic bone... allogeneic hema... peripheral bloo... mycophenolate m...	-	Fred Hutchinson Cancer Center
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer	NCT00290641	Chronic Myelopr... Leukemia Lymphoma Myelodysplastic...	filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera...	- 45 Years	Masonic Cancer Center, University of Minnesota
Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies	NCT01564277	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Contiguous Stag... de Novo Myelody... Noncontiguous S... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Adult... Stage I Adult B... Stage III Adult... Stage IV Adult ... Untreated Adult... Untreated Adult...	rasburicase allopurinol	18 Years -	Roswell Park Cancer Institute
Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission	NCT01842139	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye...	basiliximab WT1 126-134 pep... Montanide ISA 5... poly ICLC laboratory biom...	18 Years - 85 Years	University of Chicago
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer	NCT00782379	Leukemia Lymphoma Myelodysplastic...	busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo...	18 Years - 60 Years	Northside Hospital, Inc.
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia	NCT00093743	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... Fanconi Anemia Previously Trea...	fludarabine pho... cyclosporine total-body irra... allogeneic bone... allogeneic hema... peripheral bloo... mycophenolate m...	-	Fred Hutchinson Cancer Center
Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia	NCT00703300	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute... Untreated Adult...	bortezomib decitabine pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia	NCT01876953	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute... Untreated Adult...	cytarabine idarubicin dasatinib laboratory biom...	18 Years -	City of Hope Medical Center
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases	NCT00450983	Graft Versus Ho... Leukemia Myelodysplastic...	muromonab-CD3 natural killer ... fludarabine pho... methotrexate thiotepa gene expression... flow cytometry immunologic tec... allogeneic hema... in vitro-treate... total-body irra...	- 45 Years	Fred Hutchinson Cancer Center
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	NCT00475150	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult...	cediranib malea... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer	NCT00064285	Leukemia	alvocidib imatinib mesyla...	18 Years -	Virginia Commonwealth University
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia	NCT00093600	Acute Myeloid L...	cytarabine daunorubicin hy... midostaurin	18 Years - 60 Years	Novartis
Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT02316964	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute...	decitabine natural killer ... aldesleukin laboratory biom...	18 Years -	Ohio State University Comprehensive Cancer Center
Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia	NCT00618696	Leukemia Myelodysplastic...	anti-CD45 monoc... yttrium Y 90 an...	18 Years -	Masonic Cancer Center, University of Minnesota
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia	NCT00275080	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Extranodal Marg... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Secondary Acute... Splenic Margina... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Unspecified Adu... Untreated Adult... Untreated Adult...	vorinostat decitabine	18 Years -	National Cancer Institute (NCI)
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission	NCT00454168	Leukemia	PR1 leukemia pe... sargramostim placebo	18 Years -	National Cancer Institute (NCI)
Sorafenib and Low Dose Cytarabine in Older Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	NCT00516828	Leukemia Myelodysplastic...	cytarabine	60 Years -	Canadian Cancer Trials Group
DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes	NCT00397579	Leukemia Myelodysplastic... Blastic Plasmac...	DT388IL3	18 Years -	University of Texas Southwestern Medical Center
Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant	NCT00469820	Leukemia Multiple Myelom...	autologous tumo... peripheral bloo...	18 Years - 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cilengitide in Treating Patients With Acute Myeloid Leukemia	NCT00089388	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt...	cilengitide	50 Years -	National Cancer Institute (NCI)
Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia	NCT00003868	Leukemia	cyclophosphamid... methotrexate allogeneic bone... peripheral bloo... iodine I 131 mo... radiation thera...	2 Years - 55 Years	Fred Hutchinson Cancer Center
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia	NCT00276601	Leukemia	arsenic trioxid... cytarabine daunorubicin hy... mercaptopurine methotrexate tretinoin	5 Years - 74 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia	NCT00276601	Leukemia	arsenic trioxid... cytarabine daunorubicin hy... mercaptopurine methotrexate tretinoin	5 Years - 74 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia	NCT00003934	Adult Acute Mye... Adult Acute Pro... Childhood Acute... Untreated Adult... Untreated Child...	tretinoin daunorubicin hy... cytarabine mercaptopurine methotrexate arsenic trioxid...	-	National Cancer Institute (NCI)
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	NCT00131989	Adult Acute Bas... Adult Acute Eos... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Recurrent Adult... Recurrent Adult...	sorafenib tosyl... pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia	NCT00093587	Graft Versus Ho... Leukemia	anti-thymocyte ... busulfan cyclophosphamid... cyclosporine allogeneic bone... peripheral bloo... radiation thera...	18 Years - 55 Years	National Cancer Institute (NCI)
Helical Tomotherapy, Fludarabine Phosphate, and Melphalan Followed By Allo-HSCT in Hematological Malignancies	NCT00544466	Leukemia Myelodysplastic...	fludarabine pho... melphalan allogeneic hema... intensity-modul...	7 Years -	City of Hope Medical Center
Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia	NCT00666588	Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Childhood Acute... Recurrent Adult... Recurrent Child... Secondary Acute...	idarubicin cytarabine bortezomib etoposide laboratory biom...	1 Year - 21 Years	National Cancer Institute (NCI)
Vorinostat in Treating Patients With Acute Myeloid Leukemia	NCT00305773	Adult Acute Ery... Adult Acute Meg... Adult Acute Min... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Pro... Recurrent Adult... Refractory Cyto... Secondary Acute... Untreated Adult...	vorinostat vorinostat	18 Years -	National Cancer Institute (NCI)
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia	NCT00087204	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... Secondary Myelo...	becatecarin laboratory biom...	18 Years -	National Cancer Institute (NCI)
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant	NCT00376480	Leukemia Myelodysplastic...	anti-thymocyte ... peripheral bloo... fludarabine pho... methylprednisol... thiotepa allogeneic hema... in vitro-treate... total-body irra...	- 50 Years	Dana-Farber Cancer Institute
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias	NCT00098436	Leukemia	laromustine temozolomide	18 Years -	National Cancer Institute (NCI)
Individualized Exercise Programs for Patients Receiving Chemotherapy for Newly Diagnosed Acute or Relapsed Myeloid Leukemia or Lymphoblastic Leukemia	NCT00499759	Depression Fatigue Leukemia Musculoskeletal... Psychosocial Ef...	Resting vitals Body Compositio... Timed Get-up an... Cardiorespirato... Handgrip evalua... Dynamic muscula...	18 Years - 60 Years	UNC Lineberger Comprehensive Cancer Center
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer	NCT00534430	Leukemia Myelodysplastic...	busulfan cyclosporine etoposide mycophenolate m... allogeneic bone... allogeneic hema... peripheral bloo... total-body irra...	16 Years - 50 Years	City of Hope Medical Center
Healing Touch in Treating Patients Receiving Chemotherapy for Acute Myeloid Leukemia or Acute Lymphocytic Leukemia	NCT00321880	Fatigue Leukemia Psychosocial Ef...	therapeutic tou...	18 Years - 120 Years	Wake Forest University Health Sciences
Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant	NCT00376480	Leukemia Myelodysplastic...	anti-thymocyte ... peripheral bloo... fludarabine pho... methylprednisol... thiotepa allogeneic hema... in vitro-treate... total-body irra...	- 50 Years	Dana-Farber Cancer Institute
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant	NCT00107354	Leukemia Myelodysplastic...	aldesleukin therapeutic all... therapeutic aut... cytarabine etoposide mitoxantrone hy... allogeneic bone... peripheral bloo...	14 Years -	Fred Hutchinson Cancer Center
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome	NCT00475150	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute... Secondary Myelo... Untreated Adult...	cediranib malea... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT01707004	Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute...	decitabine fludarabine pho... busulfan cyclophosphamid... tacrolimus mycophenolate m... filgrastim total-body irra... allogeneic bone... laboratory biom...	18 Years - 75 Years	University of Wisconsin, Madison
Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT01246622	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult...	cytarabine lenalidomide	18 Years -	Roswell Park Cancer Institute
GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia	NCT00070551	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult...	GTI-2040 cytarabine pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission	NCT01842139	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye...	basiliximab WT1 126-134 pep... Montanide ISA 5... poly ICLC laboratory biom...	18 Years - 85 Years	University of Chicago
GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia	NCT00070551	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult...	GTI-2040 cytarabine pharmacological... laboratory biom...	18 Years -	National Cancer Institute (NCI)
Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia	NCT01174888	Acute Myeloid L... Acute Myeloid L... Myelodysplastic... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Recurrent Adult... Secondary Acute...	midostaurin Bortezomib mitoxantrone hy... etoposide cytarabine	18 Years -	Ohio State University Comprehensive Cancer Center
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	NCT00725062	Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	CD4+CD25+ regul... allogeneic hema...	18 Years - 70 Years	Masonic Cancer Center, University of Minnesota
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma	NCT00398138	Leukemia Lung Cancer Malignant Mesot... Myelodysplastic... Primary Periton...	WT-1 analog pep... incomplete Freu... sargramostim polymerase chai... flow cytometry immunoenzyme te...	18 Years - 120 Years	Memorial Sloan Kettering Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: